Cargando…

Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial

BACKGROUND: The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhandari, Sunil, Kalra, Philip A, Berkowitz, Mario, Belo, Diogo, Thomsen, Lars L, Wolf, Myles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771981/ https://www.ncbi.nlm.nih.gov/pubmed/32049331 http://dx.doi.org/10.1093/ndt/gfaa011

Ejemplares similares

Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON‐IDA/NEPHRO trials
por: Wolf, Myles, et al.
Publicado: (2020)

A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON‐EXT trial
por: Achebe, Maureen M., et al.
Publicado: (2020)

A prospective, multi‐center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON‐IDA trial
por: Auerbach, Michael, et al.
Publicado: (2019)

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
por: Bhandari, Sunil, et al.
Publicado: (2015)

Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery
por: Auerbach, Michael, et al.
Publicado: (2022)

A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose
por: Pollock, Richard F., et al.
Publicado: (2022)

Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
por: Auerbach, Michael, et al.
Publicado: (2021)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease
por: Nordfjeld, Kim, et al.
Publicado: (2012)

Introducing iron isomaltoside 1000 (Monofer®)—development rationale and clinical experience
por: Kalra, Philip A.
Publicado: (2011)

Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience
por: Jesus-Silva, Jorge A., et al.
Publicado: (2020)

Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia
por: Kalra, Philip A, et al.
Publicado: (2016)

Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients
por: Rostoker, Guy, et al.
Publicado: (2022)

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2017)

Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia
por: Derman, Richard, et al.
Publicado: (2018)

Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis
por: Schaefer, Benedikt, et al.
Publicado: (2020)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Pollock, Richard F., et al.
Publicado: (2019)

Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
por: Aksan, Ayşegül, et al.
Publicado: (2019)

Iron homeostasis in heart transplant recipients randomized to ferric derisomaltose or placebo
por: Brautaset Englund, Kristine V., et al.
Publicado: (2022)

Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial
por: Hansen, Rebecka, et al.
Publicado: (2022)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
por: Bhandari, S., et al.
Publicado: (2021)

A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000
por: Bhandari, Sunil
Publicado: (2011)

OR13-3 Effects of Iron Isomaltoside versus Ferric Carboxymaltose on Hormonal Control of Phosphate Homeostasis: The PHOSPHARE-IDA04/05 Randomized Controlled Trials
por: Wolf, Myles, et al.
Publicado: (2019)

Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
por: Emrich, I. E., et al.
Publicado: (2020)

A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
por: Pollock, Richard F, et al.
Publicado: (2017)

An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
por: Pollock, Richard F, et al.
Publicado: (2021)

Real-world experience of intravenous ferric derisomaltose evaluated through safety and efficacy reporting in the UK
por: Sinclair, Rhona C. F., et al.
Publicado: (2022)

NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2020)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Safety of intravenous iron isomaltoside for iron deficiency and iron deficiency anemia in pregnancy
por: Wesström, Jan
Publicado: (2020)

Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
por: Kawabata, Hiroshi, et al.
Publicado: (2022)

Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis
por: Goh, Hyeok Jun, et al.
Publicado: (2020)

Correction to: Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study
por: Kawabata, Hiroshi, et al.
Publicado: (2022)

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease
por: Reinisch, Walter, et al.
Publicado: (2015)

Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study
por: Kawabata, Hiroshi, et al.
Publicado: (2022)

Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017
por: Ehlken, Birgit, et al.
Publicado: (2018)

Switching iron sucrose to ferric carboxymaltose associates to better control of iron status in hemodialysis patients
por: Hofman, Jesse M. G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d0uj7krmh7lra9aim5obodb76v